Medical Device Global Market Access

The US FDA's final order on September 17, 2026, clarifies the partial 510(k) premarket notification exemption for specific AI/ML-driven radiology software. This episode breaks down the practical impact of this decision on manufacturers of computer-aided detection/diagnosis (CADe/CADx) and triage devices. We explain which devices are affected, why the FDA denied a broader exemption, and what the term "partial exemption" means for your regulatory strategy and US market access plans. Key Questions: - What did the FDA's September 17, 2026 final order on radiology AI software clarify? - Which specific types of AI/ML devices, like CADe and CADx, are impacted by...

China's NMPA has released the world's first product standard for AI-powered Brain-Computer Interface (BCI) medical devices, effective September 1, 2027. This episode breaks down the new technical requirements for the full data lifecycle—from acquisition and processing to storage and cybersecurity. We explore what this means for global manufacturers of AI/ML-enabled devices and outline practical steps for ensuring compliance to access the Chinese market. Key Questions: - What is the new NMPA standard for AI-powered BCI medical devices? - When does this new Chinese standard take effect? - Which types of medical device manufacturers are impacted by this regulation? - What ar...

China's NMPA issued a notice on September 9, 2026, significantly streamlining the regulatory process for foreign manufacturers to localize the production of imported medical devices. This episode breaks down the key changes, including the ability to leverage original overseas registration materials for domestic submissions. We discuss which companies are affected, the requirements for demonstrating substantial equivalence, and the practical steps regulatory and quality teams should take to capitalize on this new, more efficient pathway to the Chinese market. Key Questions: - What is the new NMPA policy for localizing imported medical devices in China? - How does this change, effective September 9, 2026, affect...

Mexico's health regulator, COFEPRIS, has updated the operational guidelines for Authorized Third Parties (ATPs), effective September 3, 2026. This episode explores the two main changes: the new, standardized four-year validity period for ATP authorizations and the formal separation of administrative versus technical modifications. We discuss how these updates create a more stable and predictable regulatory environment for medical device manufacturers who use the ATP pathway to expedite their market entry into Mexico, and we outline practical steps for regulatory teams to take in response. Key Questions: - What are the new COFEPRIS guidelines for Authorized Third Parties (ATPs) that took effect on...

The Saudi Food and Drug Authority (SFDA) has approved its first two locally developed AI-enabled Software as a Medical Device (SaMD) products, 'Dental IQ' and 'SAARIA,' on September 10, 2026. This episode explores the significance of this regulatory milestone, what it reveals about the SFDA's Innovative Medical Devices Pathway, and the key technical and clinical requirements for manufacturers of AI medical software seeking market access in Saudi Arabia. Key Questions: - What major regulatory milestone did the SFDA achieve on September 10, 2026? - How does the approval of 'Dental IQ' and 'SAARIA' impact the Saudi MedTech landscape? - What does this event...

Australia's Therapeutic Goods Administration (TGA) has amended the exemption criteria for Clinical Decision Support Software (CDSS), effective November 1, 2026. This episode breaks down the Therapeutic Goods Legislation Amendment (2026 Measures No. 1) Regulations 2026, explaining the clarified distinction between exempt software that 'informs' clinical decisions and regulated Software as a Medical Device (SaMD) that 'guides' or 'drives' them. We discuss the direct impact on SaMD manufacturers and provide practical, actionable steps to ensure compliance before the deadline. Key Questions: - What are the key changes to Australia's TGA exemption for Clinical Decision Support Software (CDSS) as of 2026? - When do the new TGA regulations...

India's Central Board of Indirect Taxes and Customs (CBIC) has introduced a new standardized checklist for the import clearance of medical devices, effective from early September 2026. This episode details the new requirements, the mandatory use of the e-SANCHIT portal for document submission, and how this initiative, in coordination with the CDSCO, aims to streamline customs, enhance transparency, and reduce delays for medical device importers. Key Questions: - What is the new standardized checklist for medical device imports into India? - Which Indian authorities are behind this new customs requirement? - When does the new import clearance process become mandatory? ...

This episode details China NMPA's new 'dynamic adjustment' mechanism for medical device classification, introduced in Announcements No. 52 and 53 on September 8, 2026. We explain how this shift from a static catalog to a fluid, data-driven system impacts manufacturers. The host covers the new concept of 'transitional periods' for reclassified devices and provides practical actions for regulatory and quality teams to adapt their strategies for long-term compliance and market access in China. Key Questions: - What is the new 'dynamic adjustment' mechanism for medical device classification in China? - How do NMPA Announcements No. 52 and 53 from September 8, 2026, change the regulatory landscape? - Who...

On September 6, 2026, the Saudi Food and Drug Authority (SFDA) announced legal action against a medical device company for misleading advertising. This episode breaks down the SFDA's announcement, the core principles of Saudi Arabia's medical device advertising regulations, and the potential consequences of non-compliance. We provide practical, actionable steps for manufacturers to audit their promotional materials and implement robust internal controls to ensure all marketing claims are substantiated and align with their device's approved indications. Key Questions: - What recent enforcement action did the Saudi FDA take against misleading device advertising? - Which types of advertising claims are drawing SFDA scrutiny? ...

Australia's Therapeutic Goods Administration (TGA) has introduced a new classification rule, Clause 2.2, that reclassifies non-invasive devices containing only saline for flushing or maintaining another device, such as pre-filled saline syringes, to Class IIa. This episode details the scope of the new rule, the critical compliance date of September 7, 2026, for new applications, and the five-year transition period for devices already on the Australian Register of Therapeutic Goods (ARTG). We provide practical steps for manufacturers to ensure compliance with these updated TGA device classification rules. Key Questions: - What is the new TGA Clause 2.2 and which specific combination products does it affect? ...

This episode examines the September 3, 2026, approval of the LEQEMBI (lecanemab) subcutaneous autoinjector by China's NMPA. We explore how this shift from bi-weekly IV infusions to once-weekly at-home administration impacts Alzheimer's treatment and what the NMPA's use of the Priority Review pathway signals to manufacturers of innovative drug-device combination products seeking access to the Chinese market. Key Questions: - What are the key differences between the new subcutaneous LEQEMBI formulation and the previous intravenous version? - Why did the NMPA grant this application a Priority Review? - What does this approval indicate about the NMPA's stance on innovative drug delivery systems? ...

This episode details Brazil ANVISA's Public Consultation No. 1,248, published on August 26, 2026, which proposes a new regulatory framework for the registration of Class III and IV high-risk medical devices. We discuss the key changes to technical documentation requirements, the move to align with international standards, the impact on manufacturers and their Brazilian Registration Holders (BRH), and the critical 45-day feedback period closing in October 2026. Learn the practical steps your regulatory and quality teams should take now to prepare for these significant updates to Brazil's market access requirements. Key Questions: - What is ANVISA's Public Consultation No. 1,248 and why is it important...

Brazil's ANVISA has published two new guidance manuals detailing the 'notification' pathway for Class I and II medical devices and IVDs. This episode explains how these manuals, released on August 25, 2023, clarify the submission processes under RDC 751/2022 and RDC 830/2023, what practical information they contain for manufacturers, and the concrete steps regulatory teams should take to streamline market access for lower-risk products in Brazil. Key Questions: - What are the new ANVISA guidance manuals for the notification pathway? - Which medical device and IVD classes are affected by this new guidance? - How does this guidance clarify the submission process under RDC 751/2022...

Singapore's Health Sciences Authority (HSA) launched a Registration Support Initiative on August 28, 2026, to help transition clinically important medical devices from the Special Access Route (SAR) to full market registration. This episode details the purpose of this new pathway, the eligibility criteria for devices serving small patient populations, the significant evaluation-fee waiver, and the inaugural application deadline of December 31, 2026. We provide practical steps for manufacturers to leverage this opportunity to secure a sustainable, registered supply route in Singapore. Key Questions: - What is Singapore's Special Access Route (SAR) and why is it not a long-term solution for market access? - What...

The UK government has proposed three amendments to the Health Bill, introduced on September 1, 2026, that grant significant new powers to the MHRA. This episode breaks down what these changes—enhanced information sharing, agile regulatory updates via secondary legislation, and the foundation for a future UK-specific device licensing system—mean for medical device manufacturers. We discuss the strategic implications for companies relying on CE marking for UK market access and outline practical steps that regulatory and quality teams should take now to prepare for Great Britain's move toward a sovereign regulatory framework. Key Questions: - What new powers are proposed for the...

This episode explores the significant amendments to the UK Health Bill introduced on September 1, 2026, which grant the MHRA new powers to establish a future medical device licensing regime. We analyze the potential shift from the current system of third-party UK Approved Bodies to a direct licensing model where the MHRA would approve devices. We discuss the long-term implications for manufacturers' market access strategies in Great Britain, who is affected, and the practical steps regulatory teams should consider for this evolving landscape. Key Questions: - What are the new powers granted to the UK MHRA under the 2026 Health Bill amendments? ...

The UK's MHRA has issued Device Safety Information notice DSI/2026/007, warning of non-compliant medical devices on the UK market lacking valid UKCA or CE marking. This episode breaks down the immediate actions required for healthcare providers and suppliers, such as quarantining suspect products and reporting to the MHRA. We also explore the critical implications for manufacturers, focusing on the need for enhanced post-market surveillance and rigorous supply chain oversight to prevent patient risk and ensure compliance with UK MDR 2002. Key Questions: - What is the significance of the UK MHRA's Device Safety Information notice DSI/2026/007? - Which devices are affected...

Australia's Therapeutic Goods Administration (TGA) has launched a consultation on proposals to increase the public sharing of medical device information. This episode breaks down the TGA's initiative, which was announced on August 13, 2026, and explores its potential impact on manufacturers and sponsors. We discuss the types of information that may become public, the implications for post-market surveillance and data management, and the crucial feedback deadline of October 2, 2026. Learn the practical steps your team should take now to prepare for a future of greater transparency in the Australian market. Key Questions: - What specific information does the TGA propose to make public...

Health Canada has modernized the application process for its Medical Devices Special Access Program (SAP) as of August 24, 2026. This episode details the two key changes: the introduction of a new accessible PDF application form and a new secure online submission method. We explore Health Canada's goals to reduce errors, improve data security, and accelerate review times for unauthorized devices needed for patients with serious conditions, outlining the practical steps for healthcare professionals and manufacturers. Key Questions: - What is Health Canada's Special Access Program for medical devices? - What specific changes were announced for the SAP application process on August 24, 2026? ...

The UK's MHRA issued National Patient Safety Alert NatPSA/2026/004/MHRA on August 17, 2026, for ResMed Astral 100 and 150 ventilators manufactured before October 2024. A faulty internal supercapacitor can leak, causing the device to shut down unexpectedly and risking serious injury or death. This episode details the specific device fault, the risks to patients, and the mandatory actions required by the MHRA for healthcare providers and manufacturers. We focus on the critical importance of post-market surveillance and immediate risk mitigation for life-sustaining devices. Key Questions: - What is the specific defect in ResMed Astral ventilators identified by the MHRA? - Which device models and...

China's NMPA announced the approval of 122 medical devices on August 12, 2026, including many from leading international manufacturers such as Medtronic, Roche, and Siemens. This episode breaks down this significant regulatory event, analyzing the types of devices approved—from cardiovascular and IVDs to imaging and surgical tools. We explore what this large batch of approvals reveals about the NMPA's current review priorities, the opportunities available for foreign manufacturers, and the practical steps your regulatory and market access teams should take to leverage these insights for a successful China strategy. Key Questions: - What does the NMPA's latest batch of 122 device approvals mean fo...

Singapore's Health Sciences Authority (HSA) has released its finalized 'Best Practices Guide for Medical Device Cybersecurity' (GL-10-R1), effective August 17, 2026. This episode explores the guide's three core principles—secure-by-design, shared responsibility, and transparency—and outlines their impact on manufacturers and healthcare providers. We discuss how these recommendations affect the total product lifecycle, from pre-market design to post-market surveillance, and provide actionable steps for regulatory, quality, and market-access teams to align with these new expectations. Key Questions: - What is the scope of Singapore HSA's new cybersecurity guide, GL-10-R1? - When does the new guidance become effective? - How does the...

Mexico's health authority, COFEPRIS, has launched the Medical Device Sanitary Registry Viewer, a public digital tool for verifying device registrations. This episode explores how this platform, launched on August 20, 2026, enhances market transparency and simplifies compliance. We discuss how the tool works, its impact on manufacturers, distributors, and healthcare providers, and outline practical steps for regulatory teams to adapt to this new environment. Key Questions: - What is the new COFEPRIS Medical Device Sanitary Registry Viewer? - How does this public database impact market transparency in Mexico? - What specific information can be found using the new digital tool? - How...

India's CDSCO has amended the Medical Devices Rules, 2017, effective August 24, 2024, removing the 'loan licence' requirement for manufacturers who outsource device sterilization. This episode explains the amendment, details the new mandatory labeling requirements for sterilized products, and outlines the practical steps that regulatory and quality teams must take during the six-month transition period to ensure compliance. Key Questions: - What was the 'loan licence' requirement for medical device sterilization in India? - How does the CDSCO's August 2024 amendment change the rules for outsourced sterilization? - Who is most affected by this regulatory update? - What are the new, specific labeling requirements...

The EU Notified Body landscape was shaken in August 2024 with announcements that the National Standards Authority of Ireland (NSAI) will exit its MDR designation by 2026 and TÜV NORD Scandinavia has filed for bankruptcy. This episode breaks down the immediate impact on manufacturers certified by these bodies, the broader implications for Notified Body capacity under the MDR, and the critical strategic steps regulatory teams must take now to protect their EU market access. Key Questions: - What were the specific announcements from NSAI and TÜV NORD Scandinavia in August 2024? - Why is the National Standards Authority of Ireland (NSAI) ex...

Japan's PMDA and AdvaMed are hosting a free online workshop on September 1, 2026, for U.S.-based small and mid-sized medtech companies. This episode breaks down the significance of this direct engagement opportunity, covering the key topics on the agenda—including Japan's regulatory framework, scientific advice process, and review pathways. We discuss the strategic value for manufacturers and provide practical steps your regulatory and market access teams should take to maximize the benefits of this event and de-risk your entry into the Japanese market. Key Questions: - What is the upcoming PMDA and AdvaMed workshop and who should attend? - How ca...

This episode examines the UK MHRA's Device Safety Information alert (DSI/2026/008), issued on August 18, 2026, which advises against the use of rectal catheters (gas/colic relievers) in infants. We explore why the MHRA took this precautionary action based on a lack of safety and efficacy data, rather than direct adverse event reports. The discussion focuses on the critical post-market surveillance lessons for manufacturers of direct-to-consumer medical devices, particularly those intended for vulnerable populations like children. Key Questions: - What is the UK MHRA's DSI/2026/008 and why was it issued? - Why are rectal catheters (gas/colic relievers) now considered unsafe for...

Brazil's ANVISA has opened a new pathway for innovative, high-risk medical devices. On August 5, 2026, the agency published Call Notice 5/2026, inviting manufacturers of Class III and IV devices with novel technologies to apply for a collaborative regulatory evaluation pilot program. This episode details the program's objectives, strict eligibility criteria (including AI-based devices and new biomaterials), the critical 30-day application window, and the strategic advantages of early engagement with ANVISA for accelerating market access in Brazil. Key Questions: - What is ANVISA's innovative medical device pilot program announced in August 2026? - Which types of high-risk medical devices are eligible to apply? ...

The Saudi Food and Drug Authority (SFDA) is increasing its focus on the biological evaluation of medical devices, highlighted by its upcoming workshop on August 10, 2026. This episode explores what this means for manufacturers seeking market access in Saudi Arabia. We discuss the SFDA's alignment with ISO 10993, the critical importance of a risk-based approach, and the need for a comprehensive Biological Evaluation Report (BER) in your technical dossier. Learn practical steps to review your existing data, manage material changes, and prepare for heightened regulatory scrutiny to avoid submission delays. Key Questions: - What does the SFDA's August 10, 2026 workshop on biocompatibility signal...

This episode details the US FDA's discussion paper on regulating medical devices incorporating Generative Artificial Intelligence (GenAI), released on August 18, 2026. We cover the key areas where the FDA is seeking input, including risk assessment, premarket evaluation, and postmarket monitoring for GenAI-enabled devices. We also emphasize the critical October 19, 2026, deadline for submitting feedback and provide practical steps for manufacturers to prepare and respond. Key Questions: - What is the FDA's new discussion paper on Generative AI in medical devices? - Why is the FDA seeking public feedback before issuing guidance? - What are the key risk assessment challenges for GenAI-enabled devices? ...

This episode covers the U.S. FDA's proposed rule from August 14, 2026, which aims to classify a specific list of medical device accessories as Class I. We discuss how this change would exempt these products from 510(k) premarket notification, significantly reducing the regulatory burden for manufacturers. The host details the implications for market access strategy, the cost and time savings, and highlights the critical public comment deadline of October 16, 2026, urging listeners to review the list and provide feedback. Key Questions: - What is the FDA's proposed rule from August 14, 2026, regarding medical device accessories? - Which types of accessories might be reclassified...

The Saudi Food and Drug Authority (SFDA) has implemented new mandatory requirements for medical device advertising, effective July 20, 2026. This episode breaks down the key provisions of the new guidance, MDS-REQ 8, which mandates pre-approval from the SFDA for all advertising, awareness, and charitable campaigns. We explore the broad scope of materials covered—from social media to brochures—the official submission process through the GHAD electronic system, and the critical responsibilities of manufacturers, authorized representatives, and distributors. Tune in for practical steps your regulatory and marketing teams must take to ensure compliance and maintain market access in Saudi Arabia. Key Questions: - What...

The U.S. Centers for Medicare & Medicaid Services (CMS) has introduced a major policy change with the new Regulatory Alignment for Predictable and Immediate Device (RAPID) Coverage Pathway. Announced in a procedural notice on August 7, 2026, this pathway aims to significantly reduce the delay between FDA market authorization and a national Medicare coverage decision for eligible FDA Breakthrough-designated devices. This episode breaks down the eligibility criteria for Class II and III devices, the plan for simultaneous FDA and CMS decisions, and the critical public comment deadline of October 10, 2026. We explore what this means for innovative device manufacturers and provide practical steps...

On August 12, 2026, Australia's Therapeutic Goods Administration (TGA) suspended the supply of Corpuls 3 and 3T defibrillators. This episode breaks down the TGA's precautionary action, clarifying the critical difference between a supply suspension and a device recall. We explore why the TGA acted, who is affected, and what this signals about the regulator's increasingly proactive approach to post-market surveillance. Learn the practical steps all medical device manufacturers should take to ensure their ongoing compliance in the Australian market. Key Questions: - What did Australia's TGA announce on August 12, 2026, regarding Corpuls defibrillators? - What is the critical difference between a supply suspension and...

This episode examines the UK MHRA's national alert DSI/2026/007, issued on August 10, 2026, which mandates the quarantine of medical devices supplied without the necessary UKCA or CE conformity markings. We break down the patient safety risks posed by non-compliant devices, identify the specific actions required of healthcare providers and distributors, and outline critical lessons for supply chain management and procurement to prevent future incidents. Key Questions: - What is the significance of the MHRA's national alert DSI/2026/007? - Which types of medical devices are affected by this quarantine order? - Why is a missing UKCA or CE mark a critical patient...

The UK's MHRA issued a Device Safety Information alert (DSI/2026/007) on August 10, 2026, ordering an immediate quarantine of six types of medical devices, including scalpels and blood collection sets, that were supplied without the required UKCA or CE conformity markings. This episode breaks down the MHRA's rationale, which focused on the lack of assured safety and quality due to the missing conformity assessment, even without any reported adverse events. We explore the significant market access consequences for manufacturers and distributors and provide practical steps for regulatory and quality teams to ensure supply chain integrity. Key Questions: - What did the UK...

The US FDA is considering higher user fees for overseas medical device manufacturers under the proposed MDUFA VI agreement for fiscal years 2028-2032. This episode breaks down the key takeaways from the FDA's public meeting on August 10, 2026, including the agency's rationale for the increase, the potential financial impact on non-US firms, and the critical deadlines for submitting public feedback before the proposal goes to Congress in January 2027. Key Questions: - What is MDUFA VI and why is it important for medical device manufacturers? - What specific fee changes are being proposed for overseas facilities? - What was the FDA's rationale...

This episode covers India's draft Drugs, Medical Devices and Cosmetics Bill 2026, circulated for feedback on August 7, 2026. We discuss its proposal to replace the 1940 Drugs and Cosmetics Act, creating a separate regulatory framework for medical devices, establishing a Medical Devices Technical Advisory Board (MDTAB), and enhancing enforcement powers. We explore the impact on manufacturers and provide practical steps for regulatory teams to prepare for this significant shift in India's MedTech landscape. Key Questions: - What is the new Drugs, Medical Devices and Cosmetics Bill 2026 in India? - How will this bill change the regulation of medical devices in India? - Why...

Health Canada is implementing Phase 2 of its Medical Device Establishment Licence (MDEL) modernization, with all changes coming into force on December 14, 2026. This episode provides a detailed breakdown of the key amendments published on June 17, 2026. We cover the removal of the MDEL requirement for certain foreign distributors, the new mandate for importers and distributors to provide a supplier list in their applications, and the more prescriptive requirements for documented procedures covering recalls, complaint handling, and distribution records. We provide practical steps for manufacturers, importers, and distributors to ensure compliance before the deadline. Key Questions: - What are the main changes in...

This episode covers the EU's postponement of the AI Act compliance deadline for high-risk AI medical devices to August 2, 2028. We discuss Regulation (EU) 2026/1744, explaining what this extension means for manufacturers navigating dual compliance under the MDR/IVDR and the AI Act. We offer practical steps for regulatory, quality, and market-access teams to effectively use this extra time to integrate compliance, engage with Notified Bodies, and strengthen their technical documentation. Key Questions: - What is the new EU AI Act compliance deadline for medical devices? - Which regulation officially postponed the application date? - How does the AI Act interact with...